BROAD-SPECTRUM CEPHALOSPORIN CEFTAROLINE: A NEW OPTION AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) can cause variety of hospital-acquired and community-associated infections with limited treatment options. Ceftaroline belong to cephalosporin class showed effective bactericidal activity against MRSA and several other ESBL producing gram-negative rods.

Objectives: To check the activity of ceftaroline against MRSA

Methods: This was a cross-sectional study design and was done in Pathology department of AIMC over the period of two years. MRSA isolated from different clinical samples was confirmed phenotypically and sensitivity testing for different antimicrobials was done on Mueller-Hinton agar. MIC determination of MRSA was done by E-strip method.

Results: Total 282 MRSA isolates was collected along with maximum number was isolated from pus samples (49.2%), followed by wound swabs (18.7%). MRSA isolates showed 100% sensitivity against ceftaroline and vancomycin. MIC range was 0.25 to 4 µg/mL against MRSA isolates. While maximum number of isolates of MRSA showed inhibition at 1 µg/mL.

Conclusion: Ceftaroline showed excellent bactericidal activity against MRSA and can be used effectively to treat (cSSTI). It is considered safe to use because it is well-tolerated with minimum adverse reactions.